An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

ABSTRACT: Recently, we phenocopied interleukin (IL-)6 signaling using the dimerized single-chain variable fragment (scFv) derived from the respiratory syncytial virus IgG1-antibody palivizumab (P^scFvLHFc) to activate a palivizumab antiidiotypic nanobody (AIP^VHH)-gp130 receptor fusion protein. Palivizumab was unable to activate STAT3 signaling, so we aimed to create a similar ligand capable of triggering this pathway. Here, we created three variants of the ligand called P^scFvLH0Fc, P^scFvLH4Fc and P^scFvLH8Fc by shortening the spacer region connecting P^scFvLH and Fc from 23 amino acids in P^scFvLHFc to 0 amino acids or expanding it by rigid linkers of four or eight alpha helical loops, respectively. The rigid-linker ligands had

SUBMITTER: Wittich C 

PROVIDER: S-EPMC11872477 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature